The Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) aims to strengthen sentinel surveillance for gonococcal antimicrobial resistance (AMR) in selected countries. EGASP monitors trends in antimicrobial susceptibility in Neisseria gonorrhoeae by using standardized sampling and laboratory protocols linked to epidemiological data in participating countries. EGASP contributes to the WHO global action plan on antimicrobial resistance, 2015. EGASP is a special project under the Global Antimicrobial Resistance Surveillance System (GLASS). EGASP is a collaborative effort between the WHO, the United States Centers for Disease Control and Prevention (CDC) and WHO collaborating centres on STIs. The protocol document describes the objectives and the methods of EGASP surveillance and guidance on how to implement and monitor EGASP. This publication targets the national sexually transmitted infection and antimicrobial resistance programmes and other institutions to strengthen gonorrhoea AMR surveillance system. This surveillance protocol allows collaborators to improve the quality, comparability and timeliness of gonococcal antimicrobial resistance data across multiple countries. It also aims to enhance the capacity for early detection of emergence of resistance in N. gonorrhoeae strains to recommended treatment.